Anteris enrolls & treats first patients in DurAVR THV global pivotal trial

Anteris Technologies Global Corp.

First patients enrolled and successfully treated in PARADIGM Trial for DurAVR THV in severe calcific aortic stenosis.
Procedure performed by Prof. Dr. Ole De Backer at Rigshospitalet, Copenhagen University Hospital, Denmark.
Trial is a randomized controlled study (1:1 vs commercial TAVRs) enrolling ~1,000 patients in All Comers Cohort.
Primary endpoint: all-cause mortality, all stroke, cardiovascular hospitalization at one year post procedure.
Expands existing data set of 130 patients; plans to add sites across US, Europe, and Canada.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.